PARKINSON DISEASE (Disorder)NCT02118480
Improving Functional Disability and Cognition in Parkinson Disease: Randomized Controlled Trial
A study testing cognitive remediation program: REHACOP and Occupational Therapy in people with PARKINSON DISEASE (Disorder), run by University of Deusto at 1 site in Spain.
Trial summary
The study design was a parallel-group randomized trial with equal randomization. Recruitment and enrollment were conducted between June 2012 and January 2013. At base-line, clinical, cognitive and functional data was collected. Read more about this study
- Who is it for?
- Ages 45 to 75 years
- Conditions the study is for
- PARKINSON DISEASE (Disorder)
- What is being tested?
- cognitive remediation program: REHACOP and Occupational Therapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 44 participants
- Where
- 1 siteSpain
- Study dates
- Jun 2012to Jun 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- diagnosis of PD based on the United Kingdom PD Society Brain Bank (PDSBB) diagnostic criteria
- age 45-75 years
- either male or female
- Hoehn and Yahr disease stage 1-3 as evaluated by the neurologist
Who cannot join
- the presence of dementia as defined by the (DSM-IV-TR) Diagnostic and statistical manual of mental disorders IV Test Revised and the Movement Disorders Society specific clinical criteria for PD-dementia
- the presence of other neurological illness or injury (Traumatic Brain Injury, Multiple Sclerosis)
- unstable psychiatric disorders such as schizophrenia or major depression
- the presence of visual hallucinations as assessed by the Neuropsychiatric Inventory Questionnaire (NPI-Q)
Trial locations and contacts
1 site in 1 country.
About this study
The study design was a parallel-group randomized trial with equal randomization. Recruitment and enrollment were conducted between June 2012 and January 2013. At base-line, clinical, cognitive and functional data was collected. Afterwards, the participants were randomly allocated to either the REHACOP group or the Control group. During 3 months the intervention with REHACOP program took place and at follow-up patients were again re-evaluated to evaluate the changes in clinical, cognitive and functional measures. Post-treatment assessment (finished by June 2013) was performed within the first week after completing the intervention.Optional enrollment in pre- post neuroimaging will also allow us to look at changes in the brain. Finally, longitudinal follow-up at 18 months with neuropsychological and neuroimaging assessements was also performed.
Objective: To examine the efficacy of an integrative cognitive training program (REHACOP) to improve cognition, clinical symptoms and functional disability of patients with Parkinson disease (PD).
Read the detailed description
Assessment protocol:
- Cognitive Evaluation: The cognitive battery included assessments to evaluate processing speed, verbal learning and memory, visual learning and memory and executive functioning. All cognitive measures were converted into Z-scores based on the pooled PD group, and the sign of some measures was adjusted so that higher scores indicated better cognitive performance. All composite cognitive domains maintained satisfactory internal consistency. Processing Speed (Cronbach's α = 0.85) was quantified based on the Trail Making Test-A and Salthouse Letter Comparison Test. For verbal learning and memory (α = 0.88), learning and long-term recall performance on the Hopkins Verbal Learning Test (version 2 at baseline and 4 at post-treatment) were utilized. For visual learning and memory (α = 0.96), learning and long-term recall performance on the Brief Visual Memory Test (version 1 at baseline and 3 at post-treatment) were used (α = 0.96). Executive functioning (α = 0.78) was determined based on the Stroop test, using the word-color and interference scores.
Theory of mind (TOM). The strange stories test (Happé test) was administered to evaluate TOM. Four different stories (concerning double bluff, mistakes, persuasion and white lies) were administered at baseline and follow-up, and they were summed into a total TOM score with a possible range of 0 to 8. Higher scores indicate better TOM.
- Premorbid intelligence quotient and cognitive reserve. The Accentuation Reading Test (TAP), the Spanish version of the National Adult Reading Test (NART), was administered to calculate an estimation of each patient´s premorbid intelligence. The scale ranged from 0 to 30. Cognitive reserve was estimated using the Cognitive Reserve questionnaire. This 15-item multiple-choice questionnaire includes questions about education/culture, working activity, leisure and hobbies, physical activities and social activities. Higher scores indicate a better cognitive reserve, and the scale ranged from 0 to 26.
- Global cognitive status. The Mini-Mental State Examination (MMSE) was administered to obtain a general mental status score.
- Medication use. Medications, dosages and dose frequencies were used to calculate the levodopa-equivalent daily dose (mg/day) (LEDD).
- PD assessment. The Unified Parkinson's Disease Rating Scale and the Hoehn \& Yahr scale were used for the assessment of the course and stage of the disease.
- Depressive symptoms. Geriatric Depression Scale (GDS-15) includes 15 items. Higher scores represent a higher degree of depression (range from 0 to 15).
- Neuropsychiatric symptoms. The NPI-Q was administered to evaluate neuropsychiatric symptoms. The test includes 10 items (delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, euphoria, apathy, disinhibition, irritability and aberrant motor behavior). These sub-scales were summed into a total score with a possible range of 0 to 120. Higher scores indicate more frequent and severe neuropsychiatric symptoms.
- Apathy. The Lille apathy rating scale consists of 33 items, including 9 sub-scales (everyday productivity, interests, taking initiative, novelty seeking/motivation, emotional responses, concern, social life and self-awareness). These sub-scales were summed into a total apathy score with a possible range of -36 to 36. Lower scores indicate less apathy.
- Functional disability. Functional disability was self administered using the World Health Organization Disability Assessment Schedule II (WHO-DAS II), short version (12 items).
Description of the intervention:
- REHACOP is a structured program using paper-pencil tasks and it is based on the principles of restoration, compensation and optimization with a gradually increasing level of cognitive effort and demand. REHACOP trains different cognitive domains, such as attention, memory, processing speed, language, executive functioning and social cognition. Additionally, the program includes one unit related to functional outcome: activities of daily living. REHACOP includes up to 300 different tasks hierarchically organized into at least three levels of difficulty and subtypes of abilities. Several tasks are timed, so processing speed is trained throughout various modules. Once a basic cognitive strategy has been trained and well acquired, the therapist transitions the program to the next level. The program format allows for either individual or group sessions (between 5 and 8 patients per group), although for the purpose of this study, group sessions were chosen. In this study, two psychologists conducted the REHACOP group attending 60-minute-long sessions 3 days per week at Parkinson Disease Association Biskay (ASPARBI) (two groups) or the Hospital of Galdakao (one group). Specifically, REHACOP group remediation with PD patients consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas.
- Occupational Activities: The Control group consisted of occupational group activities conducted by a psychologist at ASPARBI. The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
A subset of the sample will also complete a pre and post neuroimaging to evaluate changes in structural and functional brain activation.
- Conditions
- PARKINSON DISEASE (Disorder)
- Being tested
- cognitive remediation program: REHACOP, Occupational Therapy
- Keywords
- Parkinson disease, cognitive rehabilitation, REHACOP
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cognitive remediation program: REHACOPOther
Specifically, REHACOP group remediation with PD patients consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas.
Occupational TherapyOther
The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
| Study group | Role | What they receive |
|---|---|---|
| cognitive remediation program: REHACOP | Experimental | Cognitive rehabilitation program (REHACOP) including intervention in: attention, memory, processing speed, language, executive functioning and social cognition during 3 months, 3 times per week Receives: Other: cognitive remediation program: REHACOP |
| Occupational Therapy | Active comparator | The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood) during 3 months, 3 times per week. Receives: Other: Occupational Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in processing speed after receiving cognitive rehabilitation treatment
Measured: 3 months
Change in verbal memory performance after receiving cognitive remediation treatment
Measured: 3 months
Change in visual memory after receiving cognitive remediation treatment
Measured: 3 months
Change in executive functioning after receiving cognitive remediation treatment
Measured: 3 months
Change in theory of mind after receiving cognitive remediation treatment
Measured: 3 months
Secondary outcomes (3)
Change in apathy after receiving cognitive remediation treatment
Measured: 3 months
Change in functional disability after receiving cognitive remediation treatment
Measured: 3 months
Change in depression after receiving cognitive remediation treatment
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Apr 2014 (estimated)
- Study startJun 2012
- Primary completionJun 2013
- Study completionJun 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for PARKINSON DISEASE (Disorder)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 44 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Deusto
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Naroa Ibarretxe-Bilbao, Doctor, Principal investigator, University of Deusto
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02118480
- Sponsor's protocol ID
- NSMC-001-UD
- Status last verified
- Jan 2018
- First submitted
- 15 Apr 2014
- Last updated
- 24 Jan 2018
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Pena J, Ibarretxe-Bilbao N, Garcia-Gorostiaga I, Gomez-Beldarrain MA, Diez-Cirarda M, Ojeda N. Improving functional disability and cognition in Parkinson disease: randomized controlled trial. Neurology. 2014 Dec 2;83(23):2167-74. doi: 10.1212/WNL.0000000000001043. Epub 2014 Oct 31.
PubMed 25361785
Study at a glance
From the registry record, last updated by the sponsor on 24 Jan 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improving Functional Disability and Cognition in Parkinson Disease: Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT02118480
- Acronym / sponsor ID
- NSMC-001-UD
- Conditions
- PARKINSON DISEASE (Disorder)
- Keywords
- Parkinson disease, cognitive rehabilitation, REHACOP
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 44 participants (actual)
- Lead sponsor
- University of DeustoUniversity, hospital or other
- Study start
- Jun 2012
- Primary completion
- Jun 2013 (actual)
- Study completion
- Jun 2013 (actual)
- First posted
- 21 Apr 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study design was a parallel-group randomized trial with equal randomization. Recruitment and enrollment were conducted between June 2012 and January 2013. At base-line, clinical, cognitive and functional data was collected. Afterwards, the participants were randomly allocated to either the REHACOP group or the Control group. During 3 months the intervention with REHACOP program took place and at follow-up patients were again re-evaluated to evaluate the changes in clinical, cognitive and functional measures. Post-treatment assessment (finished by June 2013) was performed within the first week after completing the intervention.Optional enrollment in pre- post neuroimaging will also allow us to look at changes in the brain. Finally, longitudinal follow-up at 18 months with neuropsychological and neuroimaging assessements was also performed.
Objective: To examine the efficacy of an integrative cognitive training program (REHACOP) to improve cognition, clinical symptoms and functional disability of patients with Parkinson disease (PD).
Detailed description
Assessment protocol:
- Cognitive Evaluation: The cognitive battery included assessments to evaluate processing speed, verbal learning and memory, visual learning and memory and executive functioning. All cognitive measures were converted into Z-scores based on the pooled PD group, and the sign of some measures was adjusted so that higher scores indicated better cognitive performance. All composite cognitive domains maintained satisfactory internal consistency. Processing Speed (Cronbach's α = 0.85) was quantified based on the Trail Making Test-A and Salthouse Letter Comparison Test. For verbal learning and memory (α = 0.88), learning and long-term recall performance on the Hopkins Verbal Learning Test (version 2 at baseline and 4 at post-treatment) were utilized. For visual learning and memory (α = 0.96), learning and long-term recall performance on the Brief Visual Memory Test (version 1 at baseline and 3 at post-treatment) were used (α = 0.96). Executive functioning (α = 0.78) was determined based on the Stroop test, using the word-color and interference scores.
Theory of mind (TOM). The strange stories test (Happé test) was administered to evaluate TOM. Four different stories (concerning double bluff, mistakes, persuasion and white lies) were administered at baseline and follow-up, and they were summed into a total TOM score with a possible range of 0 to 8. Higher scores indicate better TOM.
- Premorbid intelligence quotient and cognitive reserve. The Accentuation Reading Test (TAP), the Spanish version of the National Adult Reading Test (NART), was administered to calculate an estimation of each patient´s premorbid intelligence. The scale ranged from 0 to 30. Cognitive reserve was estimated using the Cognitive Reserve questionnaire. This 15-item multiple-choice questionnaire includes questions about education/culture, working activity, leisure and hobbies, physical activities and social activities. Higher scores indicate a better cognitive reserve, and the scale ranged from 0 to 26.
- Global cognitive status. The Mini-Mental State Examination (MMSE) was administered to obtain a general mental status score.
- Medication use. Medications, dosages and dose frequencies were used to calculate the levodopa-equivalent daily dose (mg/day) (LEDD).
- PD assessment. The Unified Parkinson's Disease Rating Scale and the Hoehn \& Yahr scale were used for the assessment of the course and stage of the disease.
- Depressive symptoms. Geriatric Depression Scale (GDS-15) includes 15 items. Higher scores represent a higher degree of depression (range from 0 to 15).
- Neuropsychiatric symptoms. The NPI-Q was administered to evaluate neuropsychiatric symptoms. The test includes 10 items (delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, euphoria, apathy, disinhibition, irritability and aberrant motor behavior). These sub-scales were summed into a total score with a possible range of 0 to 120. Higher scores indicate more frequent and severe neuropsychiatric symptoms.
- Apathy. The Lille apathy rating scale consists of 33 items, including 9 sub-scales (everyday productivity, interests, taking initiative, novelty seeking/motivation, emotional responses, concern, social life and self-awareness). These sub-scales were summed into a total apathy score with a possible range of -36 to 36. Lower scores indicate less apathy.
- Functional disability. Functional disability was self administered using the World Health Organization Disability Assessment Schedule II (WHO-DAS II), short version (12 items).
Description of the intervention:
- REHACOP is a structured program using paper-pencil tasks and it is based on the principles of restoration, compensation and optimization with a gradually increasing level of cognitive effort and demand. REHACOP trains different cognitive domains, such as attention, memory, processing speed, language, executive functioning and social cognition. Additionally, the program includes one unit related to functional outcome: activities of daily living. REHACOP includes up to 300 different tasks hierarchically organized into at least three levels of difficulty and subtypes of abilities. Several tasks are timed, so processing speed is trained throughout various modules. Once a basic cognitive strategy has been trained and well acquired, the therapist transitions the program to the next level. The program format allows for either individual or group sessions (between 5 and 8 patients per group), although for the purpose of this study, group sessions were chosen. In this study, two psychologists conducted the REHACOP group attending 60-minute-long sessions 3 days per week at Parkinson Disease Association Biskay (ASPARBI) (two groups) or the Hospital of Galdakao (one group). Specifically, REHACOP group remediation with PD patients consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas.
- Occupational Activities: The Control group consisted of occupational group activities conducted by a psychologist at ASPARBI. The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
A subset of the sample will also complete a pre and post neuroimaging to evaluate changes in structural and functional brain activation.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| cognitive remediation program: REHACOP | Experimental | Other: cognitive remediation program: REHACOPCognitive rehabilitation program (REHACOP) including intervention in: attention, memory, processing speed, language, executive functioning and social cognition during 3 months, 3 times per week |
| Occupational Therapy | Active comparator | Other: Occupational TherapyThe activities included drawing, reading the daily news and constructing using different materials (such as paper or wood) during 3 months, 3 times per week. |
Who may qualify
- Ages
- 45 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- diagnosis of PD based on the United Kingdom PD Society Brain Bank (PDSBB) diagnostic criteria
- age 45-75 years
- either male or female
- Hoehn and Yahr disease stage 1-3 as evaluated by the neurologist
Key exclusion criteria (4 listed)
- the presence of dementia as defined by the (DSM-IV-TR) Diagnostic and statistical manual of mental disorders IV Test Revised and the Movement Disorders Society specific clinical criteria for PD-dementia
- the presence of other neurological illness or injury (Traumatic Brain Injury, Multiple Sclerosis)
- unstable psychiatric disorders such as schizophrenia or major depression
- the presence of visual hallucinations as assessed by the Neuropsychiatric Inventory Questionnaire (NPI-Q)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| cognitive remediation program: REHACOPSpecifically, REHACOP group remediation with PD patients consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas. | Other | cognitive remediation program: REHACOP |
| Occupational TherapyThe activities included drawing, reading the daily news and constructing using different materials (such as paper or wood). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group. | Other | Occupational Therapy |
Primary outcome
Change in processing speed after receiving cognitive rehabilitation treatment
Time frame: 3 months
Change in verbal memory performance after receiving cognitive remediation treatment
Time frame: 3 months
Change in visual memory after receiving cognitive remediation treatment
Time frame: 3 months
Change in executive functioning after receiving cognitive remediation treatment
Time frame: 3 months
Change in theory of mind after receiving cognitive remediation treatment
Time frame: 3 months
3 secondary outcomes
Change in apathy after receiving cognitive remediation treatment
Time frame: 3 months
Change in functional disability after receiving cognitive remediation treatment
Time frame: 3 months
Change in depression after receiving cognitive remediation treatment
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jan 2018.
- Derived from this study: PubMed 25361785Pena J, Ibarretxe-Bilbao N, Garcia-Gorostiaga I, Gomez-Beldarrain MA, Diez-Cirarda M, Ojeda N. Improving functional disability and cognition in Parkinson disease: randomized controlled trial. Neurology. 2014 Dec 2;83(23):2167-74. doi: 10.1212/WNL.0000000000001043. Epub 2014 Oct 31.
Related trials for PARKINSON DISEASE (Disorder)
Recruiting
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
Recruiting
Investigating Basal Ganglia-Cortical Physiology During Sleep and Its Modulation by Adaptive Deep Brain Stimulation in Parkinson Disease
Parkinson's Disease (PD)
Active, not recruitingPhase 2
A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease
Parkinson&Amp;#39;s Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Not yet recruiting
Cognitive-Motor Training for Gait Adaptability in Parkinson Disease
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Naroa Ibarretxe-Bilbao, Doctor principal investigator
University of Deusto
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing cognitive remediation program: REHACOP and Occupational Therapy in people with PARKINSON DISEASE (Disorder), run by University of Deusto at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in processing speed after receiving cognitive rehabilitation treatment (time frame: 3 months). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02118480, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jan 2018; AzTrials last refreshed its copy on 2 Nov 2026.